Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02671643 · ClinicalTrials.gov registry record
To Determine the Measurement Properties of the ACT in an African American Adolescent Population With Persistent Asthma
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 54
- Enrollment target
NCT02671643: Completed study, sponsored by University of North Carolina, Chapel Hill.
NCT02671643 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02671643 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 54 participants
- Enrollment target
Study Summary
Purpose: To determine the measurement properties of the asthma control test (ACT) in a prospective clinical study in an African American adolescent population.
Primary Outcome
To determine the agreement of the ACT score at the standard cutpoint of \>19 with physician assessment of control using Cohen's kappa.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2014-10 |
| Est. Completion | 2017-06-01 |
What the finished NCT02671643 record still lists
NCT02671643 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 54 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02671643 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02671643 about?
NCT02671643 is a clinical study titled "To Determine the Measurement Properties of the ACT in an African American Adolescent Population With Persistent Asthma". Purpose: To determine the measurement properties of the asthma control test (ACT) in a prospective clinical study in an African American adolescent population.
What is the current status of trial NCT02671643?
This trial is currently completed. The enrollment target is 54 participants. The study started on 2014-10. Estimated completion is 2017-06-01.
Who is sponsoring clinical trial NCT02671643?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia